Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026)

Prime Medicine has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $57.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 4.75% year-over-year to $57.8 million; the trailing twelve-month figure through Mar 2026 stood at $57.8 million (down 4.75% YoY), and the FY2025 full-year result was $58.1 million, down 8.05% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $57.8 million, down from $58.1 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $63.2 million in Q4 2024, with the low at $57.8 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $60.2 million across 3 years, with a median of $59.8 million in 2025.
• The largest YoY upside for Non-Current Deffered Revenue was 4.61% in 2025 against a maximum downside of 8.05% in 2025.
• Prime Medicine's Non-Current Deffered Revenue stood at $63.2 million in 2024, then dropped by 8.05% to $58.1 million in 2025, then declined by 0.61% to $57.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $57.8 million (Q1 2026), $58.1 million (Q4 2025), and $59.8 million (Q3 2025), per Business Quant data.